Axonics

Axonics, Inc. operates as a medical technology firm, concentrating on the development and sale of treatments for bladder and bowel dysfunction. Founded in 2012 and headquartered in Irvine, California, the company was co-founded by Raymond W. Cohen, who served as CEO until its acquisition. Cohen has an extensive background in the life sciences industry, previously leading Vessix Vascular to its acquisition by Boston Scientific and serving as CEO of Cardiac Science. His experience has been instrumental in guiding Axonics from its inception to becoming a significant player in the med-tech market, culminating in its acquisition by Boston Scientific for approximately $3.7 billion, which was announced in January 2024 and closed in November 2024.

The company's business model is centered on selling its proprietary medical devices to healthcare providers, including hospitals and urology and urogynecology clinics, through a direct sales force and distributors across the U.S. and several international markets. Axonics' revenue streams are generated from the sales of its two main product lines. For the fiscal year 2023, the company reported total net revenue of $366.4 million, a 34% increase from the previous year, with sacral neuromodulation products accounting for the majority of sales, complemented by revenue from its Bulkamid line.

The core of Axonics' portfolio is the Axonics System, a sacral neuromodulation (SNM) therapy designed to treat overactive bladder (OAB), fecal incontinence, and non-obstructive urinary retention. This system works by delivering mild electrical pulses to the sacral nerves, which helps restore normal communication between the brain and the bladder or bowel. A key feature is its rechargeable implantable neurostimulator (INS), designed to function for at least 15-20 years, a significant longevity compared to some non-rechargeable alternatives. Patients typically undergo a two-week trial with an external device before the miniature stimulator is surgically implanted.

The second major product is Bulkamid, a urethral bulking agent for women with stress urinary incontinence (SUI). Acquired by Axonics, Bulkamid is a soft, non-particulate hydrogel composed of 97.5% water and 2.5% polyacrylamide. It is injected into the urethral wall during a minimally invasive procedure to provide additional volume and support, thereby helping to prevent urine leakage. Unlike some other agents, its effect is linked to the injected volume rather than an inflammatory response, and it is not absorbed or degraded by the body.

Keywords: sacral neuromodulation, overactive bladder, fecal incontinence, urinary retention, stress urinary incontinence, medical devices, hydrogel bulking agent, neuromodulation, urology, bowel dysfunction